1-3 of 3
Xin Geng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inclacumab Reduce Preexisting Red Blood Cell Adhesion to Activated Endothelial Cells: In-Vitro Assessment of the Microfluidic Platform Endothelium-on-a-Chip

Chiara Federici, Madelyn Spehn, Pavel Kovshovik, Kara Opheim, Gabrielle Combs, Seniye Sertel, Samantha J Braxton, Allison Bode, John Zak, Xin Geng, Umut A. Gurkan
Journal: Blood
Blood (2023) 142 (Supplement 1): 5267.
https://doi.org/10.1182/blood-2023-182875
Published: 2023
Journal Articles

Preliminary Results of a Phase 1 Study in Healthy Subjects Administered Inclacumab, a Fully Human IgG4 Anti-P-Selectin Monoclonal Antibody in Development for Treatment of Sickle Cell Disease

Christina Mayer, Daniel Scott Cooper, Andrew Redfern, Xin Geng, Jianxia Shi, Mariëlle van Zutphen-van Geffen, Isabelle Kuan, Kathleen Koeck, Helen Kastrissios, Kashyap Patel, Mark Davis, Patrick Yue
Journal: Blood
Blood (2021) 138 (Supplement 1): 977.
https://doi.org/10.1182/blood-2021-153370
Published: 2021
Journal Articles

Inclacumab, a Fully Human Anti-P-Selectin Antibody, Directly Binds to PSGL-1 Binding Region and Demonstrates Robust and Durable Inhibition of Cell Adhesion

Xin Geng, Radu Mihaila, Yue Yuan, Steven Strutt, PhD, Jörg Benz, Tzechiang Tang, Christina Mayer, PharmD, Donna Oksenberg, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-140530
Published: 2020